Advancing clinical drug trials, in the blink of an eye

Recognized as innovation leaders, and experts in the field of drowsiness detection, Optalert has introduced the term blepharometry to describe the unique study of eyelid movements.

Subscribe for a free copy of the latest 2019 publication from

Dr Murray Johns
The Assessment of ‘Sleepiness’ in Human Drug Trials: A New Perspective

The Optalert BlinQ system uses infrared reflectance blepharometry and patented algorithms to accurately quantify drowsiness or wakefulness, against the validated Johns Drowsiness Scale (JDS). This future-proofed approach to clinical development, can advance clinical drug trial timelines and deliver new therapies to market faster.


Current methodologies for measuring drowsiness or wakefulness are used across a wide range of clinical drug trials including opioids, anti-depressants, shift-worker disorder and insomnia medications. Optalert’s BlinQ system is the next generation methodology for pharmaceutical drug trials which:

  • Detects and quantifies alertness, wakefulness and drowsiness
  • Monitors and measures drowsiness or alertness effects of medication
  • Ideally suited to measure dose response in clinical trials to identify the right dose (too high a dose can result in unacceptable toxicity and too low a dose can decrease the chance of showing efficacy1)
  • Provides simultaneous computerised reaction testing and Infrared reflectance recording capabilities

Optalert is now transforming the way pharmaceutical companies are able to verify the efficacy and safety of drugs in clinical trials.